Incremental prognostic value of triglyceride glucose index additional to coronary artery calcium score in asymptomatic low-risk population

Shinjeong Song1,2, Su-Yeon Choi3, Hyo Eun Park3, Hae-Won Han4, Sung Hak Park5, Jidong Sung6, Hae Ok Jung7, Ji Min Sung8 and Hyuk-Jae Chang8*

Abstract

Background: The triglyceride glucose (TyG) index has been suggested as a reliable surrogate marker of insulin resistance which is a substantial risk factor for atherosclerotic cardiovascular disease (ASCVD). Several recent studies have shown the relationship between the TyG index and cardiovascular disease; however, the role of the TyG index in coronary artery calcification (CAC) progression has not been extensively assessed especially in low-risk population.

Methods: We enrolled 5775 Korean adults who had at least two CAC evaluations. We determined the TyG index using ln (fasting triglycerides [mg/dL] x fasting glucose [mg/dL]/2). The CAC progression was defined as either incident CAC in a CAC-free population at baseline or an increase of ≥ 2.5 units between the square roots of the baseline and follow-up coronary artery calcium scores (CACSs) of subjects with detectable CAC at baseline.

Results: CAC progression was seen in 1,382 subjects (23.9%) during mean 3.5 years follow-up. Based on the TyG index, subjects were stratified into four groups. Follow-up CACS and incidence of CAC progression were markedly elevated with rising TyG index quartiles (group I [lowest]:17.6% vs. group II:22.2% vs. group III:24.6% vs. group IV [highest]: 31.3%, p < 0.001). In multivariate logistic regression analysis, the TyG index was independent predictor of CAC progression (odds ratio: 1.57; 95% confidence interval: 1.33 to 1.81; p < 0.001) especially in baseline CACS ≤ 100 group.

Conclusion: The TyG index is an independent predictor of CAC progression in low-risk population. It adds incremental risk stratification over established factors including baseline CACS.

Keywords: Triglyceride glucose index, Coronary artery calcification, Atherosclerotic cardiovascular disease

Introduction

The progression of cardiovascular (CV) disease associated with atherosclerosis is strongly associated with the risk of cardiovascular morbidity and mortality. Coronary artery calcification (CAC) is an effective marker for atherosclerosis cardiovascular disease (ASCVD) and predicts adverse outcomes. Therefore, CV risk is evaluated by the coronary artery calcium score (CACS), which is typically determined by computed tomography. In addition to baseline CACS and traditional CV risk factors, CAC progression is known as a strong predictor of mortality [1–3].

The triglyceride glucose (TyG) index has been proposed as a reliable surrogate marker for insulin resistance
(IR), a practical risk factor for ASCVD [4–6]. In addition, several studies have identified a strong relationship between the TyG index and atherosclerosis under various clinical conditions [7, 8] and relatively high CV risk patients [9–11]. It is also well known that the benefits of statin therapy are also seen in low-risk individuals. The 2019 ACC/AHA Primary Prevention Guidelines recommend that people within the of 10-years ASCVD borderline risk range (5-7.5%) consider using statins in consideration of cost efficiency and various clinical situations [12]. However, in relatively low-risk adults with atherosclerosis cardiovascular disease (ASCVD), data on the association of changes in the TyG index and CAC are limited. Therefore, in the present study, we evaluated the association of TyG in predicting CACS progression, which is known to be well related to ASCVD, in a low-risk patient group.

Methods
Study population and design
Data from the Korea Initiatives on Coronary Artery Calcification (KOICA) registry were analyzed in the present study. The KOICA is a retrospective, multicenter, and observational registry with single ethnicity in the setting of self-referral for asymptomatic subjects who underwent general health examination at six healthcare centers in South Korea [13]. Overall, 93,707 subjects were enrolled in KOICA registry from December 2012 to April 2017. Self-reported medical questionnaires were used to obtain information on previous medical history. All data were obtained during visits to each healthcare center. Among the 93,707 subjects from this registry, subjects with only on coronary artery calcium scan examination (n = 81,068), patients without available data TyG (n = 209), people under the age of 45 or over 75 (n = 779), or LDL-C cholesterol ≥ 160 mg/dL (n = 832), or diagnosis of diabetes mellitus (n = 1329), or atherosclerosis cardiovascular disease risk over low (n = 3715) were excluded. To exclude diabetic patients, we excluded both those who answered that they were currently taking antidiabetic medications in a patient self-questionnaire and those who met diagnostic criteria for diabetes from testing at the time of enrollment. Finally, 5775 subjects were analyzed (Fig. 1).

Data collection
Information on hypertension, diabetes, hyperlipidemia, and smoking was systematically collected for each subject. Weight, height, and blood pressure were measured during the healthcare center visits. Weight and height were measured during the subjects wore light clothing
without shoes. The body mass index was calculated as weight (kg)/height (m²). Blood pressure of the right arm was measured using an automatic manometer after resting for at least more than 5 min. All blood samples including total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C) low-density lipoprotein cholesterol (LDL-C), creatinine, glucose, and glycated hemoglobin A1C (HbA1C) levels were obtained after at least 8 h of fasting and analyzed. All methods were performed in accordance with the relevant guidelines and regulations.

Definitions
The TyG index was determined using ln (triglycerides [mg/dL] × glucose [mg/dL]/2). All subjects were categorized into four groups based on the quartiles of the TyG index level. CAC progression was defined as a difference ≥ 2.5 between the square roots (√) of the baseline and follow-up CACs (∆√transformed CACS) considering inter-scan variability [15]. Annualized ∆√transformed CACS was defined as ∆√transformed CACS divided by the inter-scan period.

Multi-detector CT scanners used to assess CAC had at least 16 slices (Philips Brilliance 256 ICT, and Philips Brilliance 40-channel multi-detector CT, GE 64-slice Lightspeed, Siemens 16-slice Sensation). All centers performed standard prospective or retrospective methods.

Diabetes was defined as either a fasting glucose level ≥ 126 mg/dL, HbA1C level ≥ 6.5%, a referral diagnosis of diabetes, or use of anti-diabetic treatment [16].

Statistical analysis
Continuous variables are expressed as the mean ± standard deviation; Categorical variables are presented as proportions. After checking the distribution status of variables, the one-way analysis of variance test was used to analyze continuous variables and the χ² or Fisher's exact test was used to analyze categorical variables. Multivariate linear regression analysis was used for the association of clinical variables with progression of CACS and annualized ∆√transformed CACS in overall participants. Multivariate logistic regression analysis was performed to identify independent predictors for CAC progression according to categorical baseline CACS. Sequential Cox models were performed to determine the incremental prognostic benefit of CACS over clinical data, triglyceride over both, and then glucose over the rest and in TyG index (combination parameter combing TG and glucose). A statistically significant increase in the global chi-square test of the model defined incremental prognostic value. All statistical analyses were performed using the Statistical Package for the Social Sciences version 19 (SPSS, Chicago, Illinois). A P-value < 0.05 was considered significant in all analyses.

Ethical statement
The appropriate institutional review board committees of each center approved the protocol of present study.

Results
Baseline characteristics
The mean age of the 5,775 subjects at baseline was 49 ± 5 years, and 82.6% of subjects were men (n = 4,771). The included subjects were stratified into four groups based on TyG index level. The biochemical parameters and clinical characteristics of the study subjects are presented in Table 1. TC, LDL-C, FPG, and TG levels and BMI, DBP, and SBP were elevated, whereas HDL-C Swas decreased in subjects with a high TyG index. Baseline CACS values were also higher with a higher TyG index (Fig. 2).

CACs change according to TyG index level
Table 1 presents the follow-up CACS according to TyG index. The average follow-up period was 3.5 ± 1.9 years. Follow-up CACS and incidence of CAC progression increased significantly with a rise in TyG index quartiles. Figure 3 shows that both the ∆√transformed CACS (Group I[GI] and annualized ∆√transformed CACS increased significantly with a rise in TyG index quartiles. The group with a highest TyG index had greater ∆√transformed CACS and annualized ∆√transformed CACS.

TyG index and the risk of CAC progression according to the baseline CACS
Regarding the relationship between TyG index and CAC progression according to baseline CACS, the TyG index (per unit increase) was associated with an increased risk of CAC progression in baseline CACS group 0, 1–10 and 10–100 after adjusting for age, sex, BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP) HDL-C, LDL-C, current smoking, 10-year ASCVD risk, and serum creatinine level. However, this association of TyG index with CAC progression was not observed in the group with baseline CACS > 100 (Table 2).

Incremental prognostic value of TyG in CACS progression prediction
Significant increases in global chi-square test for the Cox proportional hazards models occurred after the addition of baseline CACS to the baseline clinical model (p < 0.05) demonstrating the incremental prognostic utility of CACS in progression prediction. Additionally, the inclusion of TyG in the model led to further incremental
Fig. 2  Comparison of baseline coronary artery calcification according to triglyceride glucose index tertiles. CACS coronary artery calcium score, Group I lowest TyG index group, Group IV highest TyG index group.

Fig. 3  Change of CAC according TyG index tertiles. CAC coronary artery calcium, TyG Triglyceride glucose.
improvement in predictive accuracy above the overall combined model (including baseline clinical and CACS) (Figs. 4 and 5).

**Discussion**

In the current study, we demonstrated a significant association between CAC progression and TyG index in a group with a low to borderline 10-years ASCVD risk. Even after adjusting for cardiovascular risk factors, there were an independent association and incremental prognostic value of TyG index with CAC progression. These results are consistent with previous studies which showed association between increased TyG index level and traditional CVD risk factors [7, 17–19].

Although the mechanism underlying the association between TyG and CAC is still unclear, the TyG index is a surrogate marker of IR, which may be important. In clinical practice, TG and glycemia are among the classic markers of cardiometabolic risk. Alteration in the levels of these markers is directly associated with IR, progression of atherosclerosis and genesis of CVD. IR is defined as a clinical or experimental condition in which glucose absorption and use are impaired [20]. Previous studies have shown that IR induces an imbalance in glucose and lipid metabolism, which is associated with cardiovascular risk in various population groups [20–22]. HOMA-IR is a comparatively extensive method for IR assessment [23]. The TyG index is strongly correlated with HOMA-IR and hyperinsulinemia-normal blood glucose clamp (HIEC) and even outperforms HOMA-IR [5, 24].

In recent years, many clinical studies have shown that the TyG index correlates with the risk of developing cardiovascular disease. Sánchez Iñigo et al. and Li et al. showed that healthy participants with elevated TyG index are at higher risk of cardiovascular events in each retrospective cohort studies [18, 25]. Thai et al. reported that elevated TyG index is correlated with the incidence and severity of coronary stenosis in patients with DM [26]. Park et al. reported that the TyG index is an independent predictor of the coronary artery calcification progression [27]. Liu et al. also reported that the high TyG index increases the risk of asymptomatic myocardial damage [28]. Various studies have shown that patients with high TyG index are more likely to develop hypertension and diabetes, [19, 29] which was also confirmed in the present research. In addition, several studies proposed that the TyG index can be also prognostic factor of major adverse cardiac events in patients with acute coronary syndrome and/or percutaneous coronary intervention (PCI) and DM [30–32]. Based on these studies, some suggested using the TyG index as an indicator for determining the secondary prevention policy [33].

In several previous studies, it is well known that TyG index is a prognostic factor related to cardiovascular risk in several situations, but its meaning is relatively unknown in asymptomatic and low risk patients. The
use of the CAC score in asymptomatic subjects at intermediate risk, as determined by traditional clinical stratification methods, such as the Framingham risk score, is considered appropriate/recommended with a class IIb level of evidence by 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. The use of the CAC score is not indicated in high-risk patients, because aggressive preventive measures would already be indicated in such patients. Within the group of patients classified as being at low risk, we have attempted to identify a subgroup with a significant long-term risk of a cardiovascular event, for which preventive measures should be adopted [12].

In this study, we demonstrate that baseline CACS is also a meaningful factor for CACS progression to predict cardiovascular events in the low to borderline risk group, and the TyG index is also an independent factor for CACS progression in this group. We also found that TyG index is an incremental value that predicts CACS progression in addition to the clinical factor and baseline CAC. Therefore, considering the rationale for the prospective factor of the cardiovascular disorder of TyG in several previous studies, it is expected that it will be beneficial to consider both CACS and TyG in addition to the existing well-known clinical factor when determining the use of statins for primary prevention in a group below borderline risk.

**Limitation**

There are some limitations to the present study. The present study only included subjects who experienced at least two CAC scan examinations with available data on
Table 1 Clinical characteristics of the study cohort

|                        | Total (n = 5775) | Tertile of TyG index |
|------------------------|------------------|----------------------|
|                        |                  | I (lowest) (n = 1445) | II (n = 1443) | III (n = 1443) | IV (highest) (n = 1444) | p     |
| Age, years             | 49 ± 5           | 50 ± 6               | 49 ± 5       | 49 ± 5       | 48 ± 5                  | 0.001 |
| Male, n (%)            | 4771 (82.6)      | 956 (66.2)           | 1198 (83.0) | 1292 (89.5) | 1325 (91.8)             | < 0.001 |
| Systolic BP, mmHg      | 117 ± 14         | 115 ± 14             | 117 ± 14    | 118 ± 14    | 120 ± 14                | < 0.001 |
| Diastolic BP, mmHg     | 74 ± 11          | 72 ± 11              | 74 ± 11     | 75 ± 10     | 77 ± 10                 | < 0.001 |
| BMI, kg/m2             | 24.4 ± 2.6       | 23.2 ± 2.6           | 24.1 ± 2.4  | 24.7 ± 2.5  | 25.5 ± 2.5              | < 0.001 |
| Current smoking, n (%) | 2275 (39.4)      | 515 (35.6)           | 577 (40.0)  | 570 (39.5)  | 613 (42.5)              | < 0.001 |
| Total cholesterol, mg/dL | 198 ± 29     | 188 ± 28             | 194 ± 28    | 200 ± 29    | 208 ± 29                | < 0.001 |
| Triglyceride, mg/dL    | 136 ± 79         | 66 ± 13              | 99 ± 13     | 139 ± 20    | 240 ± 82                | < 0.001 |
| HDL-C, mg/dL           | 54 ± 12          | 61 ± 13              | 55 ± 11     | 51 ± 11     | 46 ± 10                 | < 0.001 |
| LDL-C, mg/dL           | 123 ± 26         | 114 ± 24             | 124 ± 25    | 128 ± 26    | 128 ± 26                | < 0.001 |
| Glucose, mg/dL         | 93 ± 12          | 87 ± 9               | 92 ± 10     | 94 ± 10     | 99 ± 16                 | < 0.001 |
| HbA1C, %               | 5.5 ± 0.4        | 5.4 ± 0.3            | 5.4 ± 0.4  | 5.5 ± 0.4  | 5.6 ± 0.5              | < 0.001 |
| Creatinine, mg/dL      | 0.95 ± 0.16      | 0.91 ± 0.18          | 0.95 ± 0.16 | 0.97 ± 0.15 | 0.97 ± 0.15          | < 0.001 |
| TyG index              | 9.30 ± 0.55      | 8.63 ± 0.22          | 9.10 ± 0.10 | 9.46 ± 0.11 | 10.0 ± 0.29          | < 0.001 |
| ASCVD risk, %          | 3.3 ± 1.9        | 2.6 ± 1.9            | 3.2 ± 1.9  | 3.6 ± 1.8  | 4.1 ± 1.8              | < 0.001 |
| Observation time (years)| 3.5 ± 1.9        | 3.4 ± 1.8            | 3.5 ± 1.9  | 3.5 ± 1.9  | 3.6 ± 1.9              | 0.071 |

Table 2 Impact of the TyG index (per 1 unit increase) on CAC progression based on baseline categorical CACS

|                        | OR (95% CI) | p     |
|------------------------|------------|-------|
| Total population       |            |       |
| Model 1                | 1.73 (1.55–1.94) | < 0.001 |
| Model 2                | 1.57 (1.36–1.81) | < 0.001 |
| CACS 0                 |            |       |
| Model 1                | 1.61 (1.36–1.98) | < 0.001 |
| Model 2                | 1.55 (1.22–1.96) | < 0.001 |
| CACS 1–10              |            |       |
| Model 1                | 1.62 (1.20–2.19) | 0.002 |
| Model 2                | 1.43 (1.03–1.98) | 0.034 |
| CACS 10–100            |            |       |
| Model 1                | 1.39 (1.10–1.75) | 0.006 |
| Model 2                | 1.37 (1.04–1.81) | 0.025 |
| CACS >100              |            |       |
| Model 1                | 1.65 (1.14–2.38) | 0.008 |
| Model 2                | 1.41 (0.94–2.11) | 0.094 |

Models: 1 = unadjusted; 2 = adjusted for age, sex, BMI, SBP, DBP, HDL-C, LDL-C, current smoking, and serum creatinine level

BMI: Body mass index, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, CAC: Coronary artery calcification, CACS: Coronary artery calcium score, CI: Confidence interval, OR: Odds ratio, TyG: Triglyceride glucose

Table 2 Impact of the TyG index (per 1 unit increase) on CAC progression based on baseline categorical CACS

- Conclusion
  - This study is unique in that it identified the incremental value of the TyG index for CAC progression in addition to baseline CAC status in a large sample of low to borderline asymptomatic risk adults.

Abbreviations
- ASCVD: Atherosclerosis-related cardiovascular disease
- BMI: Body mass index
- CV: Cardiovascular
- CAC: Coronary artery calcification
- CACS: Coronary artery calcium score
- CI: Confidence interval
- HDL-C: Highdensity lipoprotein cholesterol
- KOICA: Korea Initiatives on Coronary Artery Calcification
- LDL-C: Low-density lipoprotein cholesterol
- TyG: Triglyceride glucose

Acknowledgements
- This work was supported by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, Republic of Korea, the Ministry of Food and Drug Safety) (Project Number: 202016B02).

Author contributions
- All authors have made substantial contributions. SS and JMS performed the statistical analysis. SS drafted the manuscript. SYC, HEP, HWH, SHP, JS, JHL SYC,
EJC, SHP, HWH, JS, HDJ, and HJC contributed to data acquisition. SS and HJC contributed to the interpretation of data. HJC critically reviewed the manuscript. All authors also gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy. All authors read and approved the final manuscript.

Funding
Not applicable.

Declarations

Ethics approval and consent to participate
The study was conducted according to the 1964 Declaration of Helsinki and its later amendments.

Consent for publication
The manuscript was approved by all authors for publication.

Competing interests
The authors have no competing interests to declare.

Author details
1 Division of Cardiology, Department of Internal Medicine, Ewha Womans University Hospital, Ewha Womans University College of Medicine, Seoul, South Korea. 2 Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea. 3 Division of Cardiology, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, South Korea. 4 Department of Internal Medicine, Gangnam Heartscast Clinic, Seoul, South Korea. 5 Division of Radiology, Gangnam Heartscast Clinic, Seoul, South Korea. 6 Division of Cardiology, Heart Stroke & Vascular Institute, Samsung Medical Center, Seoul, South Korea. 7 Division of Cardiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 8 Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System. 90-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul, South Korea.

Received: 16 August 2022 Accepted: 3 September 2022
Published online: 23 September 2022

References
1. Budof MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi P, Berman DS. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49(18):1860–70.
2. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklm M, Bluemke DA, O’Leary DH, Tracy R, Watson K, Wong ND, Kromal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–45.
3. Budof MJ, Hokanson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, Demoss D, Nuguri V, Nabavi V, Ratnakonda R, Berman DS, Raggi P. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging. 2010;3(12):129–36.
4. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25(7):1177–84.
5. Vasques AC, Novaes FS, de Oliveira MS, Souza JR, Yamanaka A, Pareja JC, Tambascia MA, Saad MJ, Golenze B. TyG index performs better than HOMA in a Brazilian population: a hyperglycemic clamp validated study. Diabetes Res Clin Pract. 2011;93(3):e98–100.
6. Guerrero-Romero F, Villalobos-Molina R, Jiménez-Flores JR, Simental-Mendia LE, Méndez-Cruz R, Murguía-Romero M, Rodríguez-Morán M. Fasting triglycerides and glucose index as a diagnostic test for insulin resistance in young adults. Arch Med Res. 2016;47(5):382–7.
7. Kim MK, Ahn OW, Kang S, Nam JS, Kim KR, Park J. Relationship between the triglyceride glucose index and coronary artery calcification in Korean adults. Cardiovasc Diabetol. 2017;16(1):108.
8. Won KB, Kim YS, Lee BK, Heo R, Han D, Lee JH, Lee SE, Sung JM, Cho I, Park HB, Cho I, Chang HJ. The relationship of insulin resistance estimated by triglyceride glucose index and coronary plaque characteristics. Medicine. 2018;97(21):e10726.
9. Won KB, Park GM, Lee SE, Cho IU, Kim HC, Lee BK, Chang HJ. Relationship of insulin resistance estimated by triglyceride glucose index to arterial stiffness. Lipids Health Dis. 2018;17(1):268.
10. Ma X, Dong L, Shao Q, Cheng Y, Lv S, Sun Y, Shen H, Wang Z, Zhou Y, Liu X. Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):1–14.
11. Jin JL, Gao YX, Wu LG, You XD, Guo YL, Wu NQ, Zhu CG, Gao Y, Dong QT, Zhang HW, Sun D. Triglyceride glucose index for predicting cardiovascular outcomes in patients with coronary artery disease. J Thorac Dis. 2018;10(11):6137–46.
12. Nam K-W. Hyung-Min Kwon & Lee Y-S. High triglyceride-glucose index is associated with early recurrent ischemic lesion in acute ischemic stroke. Sci Rep. 2021;11(1):1–8.
13. Donna K, Arnett RS, Binzelthall MA, Albert AB, Buroker ZD, Goldberger Ellen J, Hahn CD, Himmelfarba K, Khera D, Lloyd-Jones JM, William McEvoy ED, Miedema Michos MD, Muñoz Daniel, Smith SC Jr, Virani SS, Williams KA Sr, Yebob a, Ziaeian B. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;2019(140):e596–646.
14. Lee JH, Han D, Park HE, Choi SY, Sung J, Park SH, Han HW, Jung HQ, Chun EJ, Chang HJ. Coronary artery calcification in the Asian population: an overview of the results from the Korea initiatives on coronary artery calcification registry. Cardiovasc Imaging Asia. 2017;1(2):89–98.
15. Agatston AS, Janowitz WR, Hildner FJ, Zsuzska NR Jr, Vlambote M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827–32.
16. Hokanson JE, MacKenzie T, Kinney G, Snell-Becken JG, Dabelea D, Ehrlich J, Eckel RH, Revers M. Evaluating changes in coronary artery calcium: an analytical approach that accounts for interscan variability. AJR Am J Roentgenol. 2004;182(S5):1327–32.
17. American Diabetes Association. Standards of medical care in diabete—2014. Diabetes Care. 2014;37(Supplement_1):14–80.
18. Lee EY, Yang HK, Lee J, et al. Triglyceride glucose index, a marker of insulin resistance, is associated with coronary artery stenosis in asymptomatic subjects with type 2 diabetes. Lipids Health Dis. 2016;15:155.
19. Sánchez-Áñigo L, Navarro-González D, Fernández-Montero A, Pastrana-Delgado J, Martínez J. The TyG index may predict the development of cardiovascular events. Eur J Clin Invest. 2016;46(2):189–97.
20. Zheng R, Mao Y. Triglyceride and glucose (TyG) index as a predictor of incident hypertension: a 9-year longitudinal population-based study. Lipids Health Dis. 2017;16:175.
21. Ormazabal V, Nair S, Ellefy O, Aguayo C, Salomon C, Zuniga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018;17(1):122.
22. Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care. 2002;25(7):1177–84.
23. Laakso M, Kuusi L. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293–302.
24. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Maunani T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23(1):57–63.
25. Guerrero-Romero F, Simental-Mendia LE, González-Ortiz M, Martínez-Abundis E, Ramos-Zavallo MG, Hernández-González SO, Jacques-Camarena O, Rodríguez-Moran M. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–51.
26. Li S, Guo B, Chen H, Shi Z, Li Y, Tian Q, Shi S. The role of the triglyceride (triacylglycerol) glucose index in the development of cardiovascular events: a retrospective cohort analysis. Sci Rep. 2019;9(1):7320.
27. Thai PV, Tien HA, Van Minh H, Valensi P. Triglyceride glucose index for the detection of asymptomatic coronary artery stenosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2020;19(1):137.
28. Park K, Ahn CW, Lee SB, Kang S, Nam JS, Lee BK, Kim JH, Park JS. Elevated TyG index predicts progression of coronary artery calcification. Diabetes Care. 2019;42(8):1569–73.

29. Liu Y, Wu M, Xu J, Sha D, Xu B, Kang L. Association between Triglyceride and glucose (TyG) index and subclinical myocardial injury. Nutr Metab Cardiovasc Dis. 2020;30(11):2072–6.

30. Sanchez-Inigo L, Navarro-Gonzalez D, Pastrana-Delgado J, Fernandez-Montero A, Martinez JA. Association of triglycerides and new lipid markers with the incidence of hypertension in a Spanish cohort. J Hypertens. 2016;34(7):1257–65.

31. Ma X, Dong L, Shao Q, Cheng Y, Lv S, Sun Y, Shen H, Wang Z, Zhou Y, Liu X. Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):31.

32. Wang L, Cong HL, Zhang JX, Hu YC, Wei A, Zhang YY, Yang H, Ren LB, Qi W, Li WT, et al. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome. Cardiovasc Diabetol. 2020;19(1):80.

33. Hu C, Zhang J, Liu J, Liu Y, Gao A, Zhu Y, Zhao Y. Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular events: a cohort study from China. Cardiovasc Diabetol. 2020;19(1):116.

34. da Silva A, Caldas AP, Hermsdorff HH, Bersch-Ferreira AC, Torreglosa CR, Weber B, Bressan J. Triglyceride-glucose index is associated with symptomatic coronary artery disease in patients in secondary care. Cardiovasc Diabetol. 2019;18(1):89.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.